Reading view
Slovak Conceptual Dictionary
Wikontic: Constructing Wikidata-Aligned, Ontology-Aware Knowledge Graphs with Large Language Models
Deep Learning-Based Computer Vision Models for Early Cancer Detection Using Multimodal Medical Imaging and Radiogenomic Integration Frameworks
Multi-Modal AI for Remote Patient Monitoring in Cancer Care
Will Humanity Be Rendered Obsolete by AI?
Life-Code: Central Dogma Modeling with Multi-Omics Sequence Unification
The AI Productivity Index (APEX)
Opinion: Racial bias in medicine can be as simple as dismissing Black patients as a ‘hard stick’
I was moments away from a routine screening colonoscopy when it happened again. The warm and professional pre-procedure nurse began preparing for intravenous insertion. She tied the tourniquet loosely around my arm, took a quick glance, and untied it within seconds. “I can’t find a vein. You must be dehydrated,” she said, moving immediately to the back of my hand.
I paused. I didn’t feel dehydrated. Yes, I had followed the bowel prep instructions, consuming only liquids the day before, but I had no signs of dehydration. I knew my body. I knew my veins.


© AIZAR RALDES/AFP via Getty Images
The role of digital twins in P4 medicine: A paradigm for modern healthcare
npj Digital Medicine, Published online: 01 December 2025; doi:10.1038/s41746-025-02115-x
The role of digital twins in P4 medicine: A paradigm for modern healthcareDNA-Based Liquid Biopsy for Evaluating Surgical and Postsurgical Outcomes in Gynecologic Malignancies: A Systematic Review
J Clin Lab Anal. 2025 Dec 1:e70139. doi: 10.1002/jcla.70139. Online ahead of print.
ABSTRACT
INTRODUCTION: DNA-based liquid biopsies, including circulating tumor DNA (ctDNA) and cell-free DNA (cfDNA), are emerging as minimally invasive biomarkers for monitoring surgical and postsurgical outcomes in gynecologic malignancies. These tools offer the potential to guide early intervention, refine risk stratification, and improve prognostic accuracy. This systematic review aimed to assess the clinical utility of DNA-based liquid biopsies in evaluating recurrence, surgical success, and preoperative diagnosis in gynecologic cancers.
METHODS: A systematic review was conducted in accordance with PRISMA guidelines, covering studies published from 2017 to 2025. Literature searches were performed in PubMed, Scopus, and Web of Science. A total of 32 eligible observational studies involving 3210 patients with ovarian, endometrial, uterine, and other gynecologic malignancies were included. Study quality was assessed using the Newcastle-Ottawa Scale (NOS).
RESULTS: The studies showed a broad geographic and methodological diversity, with a median NOS score of 7. CtDNA and cfDNA demonstrated promise in three key areas: (1) Recurrence prediction-postoperative ctDNA positivity was associated with higher relapse rates and reduced disease-free survival; (2) Monitoring surgical outcomes and treatment response-ctDNA dynamics more accurately reflected tumor burden than traditional markers like CA125; (3) Preoperative diagnostic support-cfDNA methylation profiling and cfDNA/CA125 models enhanced malignancy detection and risk stratification. Ovarian and endometrial cancers were most frequently studied.
CONCLUSIONS: DNA-based liquid biopsies show strong potential in perioperative care for gynecologic cancers. Their integration into clinical workflows could improve the detection of minimal residual disease and inform individualized surgical planning.
PMID:41327898 | DOI:10.1002/jcla.70139
Acceptability of Health Information Technology by Health Care Professionals: Where We Are Now and How We Can Fill the Gap
AI-Enhanced Social Robotic Versus Computer-Based Virtual Patients for Clinical Reasoning Training in Medical Education: Observational Crossover Cohort Study
Monitoring of circulating tumor DNA allows early detection of disease relapse in patients with operable breast cancer
Mol Oncol. 2025 Nov 27. doi: 10.1002/1878-0261.70170. Online ahead of print.
ABSTRACT
Breast cancer is known for late recurrences, yet current follow-up lacks radiological or blood-based monitoring for systemic relapse. This study evaluated circulating tumor DNA (ctDNA) monitoring for early detection of systemic relapse after curative treatment. In this case-control study of 70 patients with operable breast cancer (35 with relapse and 35 without relapse), blood samples were collected every 6-12 months during a median 8.3-year follow-up. ctDNA was analyzed by targeted DNA sequencing using Oncomine™ Breast cfDNA Research Assay v2, and results were compared to genetic analysis of tumor and metastasis biopsies. ctDNA was detected at relapse in 19 of 35 (54%) patients with disease relapse and preceded clinical or radiological relapse detection in 17, with a median lead time of 10.3 months. In 13 (68%) patients, there was concordance with tumor mutations, and in seven patients, there was also concordance with metastasis. Among the relapse-free patients, seven were ctDNA-positive postsurgery, and only one of them had a match among the tumor variants. These findings suggest serial ctDNA analysis may enable earlier detection of systemic relapse in patients with operable breast cancer.
PMID:41307327 | DOI:10.1002/1878-0261.70170
Research progress in computer-aided diagnosis systems for lung cancer
npj Digital Medicine, Published online: 26 November 2025; doi:10.1038/s41746-025-02101-3
Research progress in computer-aided diagnosis systems for lung cancerCognitive bias in LLM reasoning compromises interpretation of clinical oncology notes
Rigor in AI: Doing Rigorous AI Work Requires a Broader, Responsible AI-Informed Conception of Rigor
Smart spatial omics (S2-omics) optimizes region of interest selection to capture molecular heterogeneity in diverse tissues
Nat Cell Biol. 2025 Nov 26. doi: 10.1038/s41556-025-01811-w. Online ahead of print.
ABSTRACT
Spatial omics technologies have transformed biomedical research by enabling high-resolution molecular profiling while preserving the native tissue architecture. These advances provide unprecedented insights into tissue structure and function. However, the high cost and time-intensive nature of spatial omics experiments necessitate careful experimental design, particularly in selecting regions of interest (ROIs) from large tissue sections. Currently, ROI selection is performed manually, which introduces subjectivity, inconsistency and a lack of reproducibility. Previous studies have shown strong correlations between spatial molecular patterns and histological features, suggesting that readily available and cost-effective histology images can be leveraged to guide spatial omics experiments. Here we present Smart Spatial omics (S2-omics), an end-to-end workflow that automatically selects ROIs from histology images with the goal of maximizing molecular information content in the ROIs. Through comprehensive evaluations across multiple spatial omics platforms and tissue types, we demonstrate that S2-omics enables systematic and reproducible ROI selection and enhances the robustness and impact of downstream biological discovery.
PMID:41298871 | DOI:10.1038/s41556-025-01811-w
Information content as a health system screening tool for rare diseases
npj Digital Medicine, Published online: 25 November 2025; doi:10.1038/s41746-025-02096-x
Information content as a health system screening tool for rare diseases